Ignite Creation Date:
2025-12-24 @ 6:59 PM
Ignite Modification Date:
2025-12-30 @ 10:21 PM
Study NCT ID:
NCT04828057
Status:
COMPLETED
Last Update Posted:
2022-10-31
First Post:
2021-03-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
Sponsor:
Santen Pharmaceutical (Taiwan) Co., LTD
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-09-01
Start Date Type:
ACTUAL
Primary Completion Date:
2022-08-24
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-08-24
Completion Date Type:
ACTUAL
First Submit Date:
2021-03-22
First Submit QC Date:
None
Study First Post Date:
2021-04-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-10-27
Last Update Post Date:
2022-10-31
Last Update Post Date Type:
ACTUAL